Jeffrey Enejosa

3.3k total citations · 3 hit papers
45 papers, 2.6k citations indexed

About

Jeffrey Enejosa is a scholar working on Infectious Diseases, Rheumatology and Hepatology. According to data from OpenAlex, Jeffrey Enejosa has authored 45 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 16 papers in Rheumatology and 12 papers in Hepatology. Recurrent topics in Jeffrey Enejosa's work include HIV/AIDS drug development and treatment (17 papers), Rheumatoid Arthritis Research and Therapies (13 papers) and Hepatitis C virus research (12 papers). Jeffrey Enejosa is often cited by papers focused on HIV/AIDS drug development and treatment (17 papers), Rheumatoid Arthritis Research and Therapies (13 papers) and Hepatitis C virus research (12 papers). Jeffrey Enejosa collaborates with scholars based in United States, Brazil and Australia. Jeffrey Enejosa's co-authors include Andrew Cheng, Edwin DeJesus, Joel E. Gallant, Anton Pozniak, José Ramón Arribas, Damian J. McColl, Rafael Campo, Brian Gazzard, John J. Toole and Steven L. Chuck and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Hepatology.

In The Last Decade

Jeffrey Enejosa

44 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

2006 703 citations Joel E. Gallant, Edwin DeJesus et al. profile →
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

2020 181 citations Jeffrey Enejosa, Aileen L. Pangan et al. profile →
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

2020 180 citations Stanley Cohen, Ronald van Vollenhoven et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Jeffrey Enejosa

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Enejosa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Enejosa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Enejosa more than expected).

Fields of papers citing papers by Jeffrey Enejosa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Enejosa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Enejosa. The network helps show where Jeffrey Enejosa may publish in the future.

Co-authorship network of co-authors of Jeffrey Enejosa

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Enejosa. A scholar is included among the top collaborators of Jeffrey Enejosa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Enejosa. Jeffrey Enejosa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program 2021 ·Drug Safety ·Philip G. Conaghan, Eduardo Mysler, Yoshiya Tanaka, (unknown), Tim Shaw, John Liu, Ryan Ferguson, Jeffrey Enejosa, Stanley Cohen, Peter Nash, William F. C. Rigby, Gerd R Burmester	33
2	Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program 2021 ·Lara D. Veeken ·Charles Peterfy, Vibeke Strand, Alan Friedman, Stephen Hall, Eduardo Mysler, Patrick Durez, Xenofon Baraliakos, Jeffrey Enejosa, Tim Shaw, Yihan Li, Su Chen, In‐Ho Song	8
3	P209 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme 2020 ·Lara D. Veeken ·Stanley Cohen, Ronald van Vollenhoven, Kevin Winthrop, Cristiano A. F. Zerbini, Yoshiya Tanaka, Louis Bessette, Ying Zhang, Nasser Khan, Barbara A. Hendrickson, Jeffrey Enejosa, Gerd R Burmester	1
4	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme breakdown → 2020 ·Annals of the Rheumatic Diseases ·Stanley Cohen, Ronald van Vollenhoven, Kevin Winthrop, Cristiano A. F. Zerbini, Yoshiya Tanaka, Louis Bessette, Ying Zhang, Nasser Khan, Barbara A. Hendrickson, Jeffrey Enejosa, Gerd R Burmester	180
5	THU0191 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-MONOTHERAPY STUDY 2019 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Paul Emery, William F. C. Rigby, Yoshiya Tanaka, Juan Ignacio Vargas, Nemanja Damjanov, (unknown), Yunxia Sui, Jeffrey Enejosa, Aileen L. Pangan, Heidi S. Camp, Stanley Cohen	2
6	Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response 2019 ·Annals of the Rheumatic Diseases ·Roy Fleischmann, Mark C. Genovese, Jeffrey Enejosa, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J.K. Östör, Yihan Li, In‐Ho Song	115
7	SAT0244 Impact of 12 weeks of upadacitinib treatment on individual and composite disease measures in patients with rheumatoid arthritis and inadequate response to conventional synthetic or biologic dmards 2018 ·Annals of the Rheumatic Diseases ·Ronald van Vollenhoven, Robin K. Dore, (unknown), Heidi S. Camp, Jeffrey Enejosa, T. Shaw, (unknown), Stephen Hall	1
8	A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus 2015 ·AIDS ·Melanie Thompson, Michael S. Saag, Edwin DeJesus, Joseph Gathe, Jay Lalezari, Alan Landay, Jerry Cade, Jeffrey Enejosa, Éric Lefebvre, Judith Feinberg	67
9	SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin 2014 ·Hepatology ·Massimo Colombo, Ola Weiland, Daniel E. Cohen, Jean‐François Dufour, Hendrik Reynaert, M. Diago, Erica Villa, Adrian Streinu‐Cercel, Wangang Xie, Tolga Baykal, Jeffrey Enejosa, Eoin Coakley, Roger Trinh, Thomas Podsadecki	2
10	ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection 2014 ·Gastroenterology ·Pietro Andreoné, Massimo Colombo, Jeffrey Enejosa, İftihar Köksal, Péter Ferenci, A Maieron, Beat Müllhaupt, Yves Horsmans, Ola Weiland, H. W. Reesink, Lino Rodrigues, Yiran Hu, Thomas Podsadecki, Barry Bernstein	273
11	A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression 2014 ·The Pediatric Infectious Disease Journal ·Xavier Sáez‐Llorens, Elizabeth Castaño, Mobeen H. Rathore, Joseph A. Church, Jaime G. Deville, Aditya H. Gaur, Dora Estripeaut, Kirsten White, Sarah Arterburn, Jeffrey Enejosa, Andrew Cheng, Steven L. Chuck, Martin S. Rhee	15
12	818Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients, by Baseline Demographics 2014 ·Open Forum Infectious Diseases ·Ronald Nahass, John M. Vierling, Hans Van Vlierberghe, David Wyles, Maurizia Rossana Brunetto, Wangang Xie, Daniel E. Cohen, Yan Luo, Jeffrey Enejosa	0
13	A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected Adolescents 2012 ·The Pediatric Infectious Disease Journal ·Marinella Della Negra, (unknown), (unknown), Marcos Tadeu Nolasco da Silva, Jorge Pinto, Kirsten White, Sarah Arterburn, Ya-Pei Liu, Jeffrey Enejosa, Andrew Cheng, Steven L. Chuck, Martin S. Rhee	22
14	Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial 2010 ·The Journal of Infectious Diseases ·Andrew Zolopa, Daniel S Berger, Harry Lampiris, Lijie Zhong, Steven L. Chuck, Jeffrey Enejosa, Brian P. Kearney, Andrew Cheng	103
15	Pharmacokinetics of tacrolimus co‐administered with adefovir dipivoxil to liver transplant recipients 2009 ·Liver International ·Norah A. Terrault, Tram T. Tran, Eugene R. Schiff, Brendan M. McGuire, Robert S. Brown, Rebecca Tupper, Srini Ramanathan, Jeffrey Enejosa, Lijie Zhong, Jian Zong, (unknown)	2
16	The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients 2008 ·AIDS ·Joel E. Gallant, Jonathan Winston, Edwin DeJesus, Anton Pozniak, (unknown), Andrew Cheng, Jeffrey Enejosa	95
17	Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients 2008 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·José Ramón Arribas, Anton Pozniak, Joel E. Gallant, Edwin DeJesus, Brian Gazzard, Rafael Campo, (unknown), Damian J. McColl, Charles B. Holmes, Jeffrey Enejosa, John J. Toole, Andrew Cheng	184
18	Pharmacokinetics of Coadministered Ritonavir-Boosted Elvitegravir and Zidovudine, Didanosine, Stavudine, or Abacavir 2007 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·S. Ramanathan, Gong Shen, John E. Hinkle, Jeffrey Enejosa, Brian P. Kearney	28
19	The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching Therapy 2007 ·HIV Clinical Trials ·José Valdez Madruga, Isabel Cassetti, Jamal Suleiman, Arnaldo Etzel, Lijie Zhong, Charles B. Holmes, Andrew Cheng, Jeffrey Enejosa, (unknown)	54
20	Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anton Pozniak, Joel E. Gallant, Edwin DeJesus, José Ramón Arribas, Brian Gazzard, Rafael Campo, (unknown), Damian J. McColl, Jeffrey Enejosa, John J. Toole, Andrew Cheng	184

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact